22 April 2026
Signal detail
· delta −0.05 PCAC has 6 vacancies including the chair. STAT reports advisers are "expected to support" RFK's legalization push. The mechanism is now structural: Kennedy controls who reviews the peptides, not just the political framing. The not-Cat-1 prediction survives on the conditional-Cat-1 pathway — even under political pressure, adding conditions or caveats to BPC-157 (given its absent safety dossier) is the bureaucratic path of least resistance. ProPublica and former FDA officials (Woodcock) are building the counter-narrative publicly, but their objections are scientific in a process that has become political.
Kennedy fills all 6 PCAC vacancies with pro-access members before July 23. Career FDA staff resistance becomes irrelevant. Full unrestricted Cat 1 is granted as political choreography.
Same PCAC vacancy mechanism applies. The at-least-2-of-4 threshold is forgiving: even if the panel only passes BPC-157 and TB-500 (which have more clinical attention) while deferring MOTs-C and KPV, the prediction resolves true. The DSHEA 1994 analogy holds — batch reclassification accelerates under political momentum. Blanket deferral of all four is the live counter-case but requires career scientists to override both political pressure and a committee potentially stacked with sympathetic appointees.
Safety dossiers are too weak across all four; even a friendly panel defers the entire batch pending additional data submission.
Confirming signals across multiple sources. Novo Nordisk settlement removes legal distraction and confirms Hims as a branded GLP-1 distributor alongside its compounding/peptide ambitions. BofA flags upside. Eucalyptus acquisition shows international telehealth platform commitment. May 11 earnings is the next genuine catalyst — Q1 revenue guided $600–625M but EPS expected down 70% YoY. Watch for peptide launch timeline mentions and California facility capital allocation.
PCAC deferral + earnings miss + cash preservation forces peptide launch delay to 2027.
Held steady. ProPublica and Woodcock are building the investigative narrative infrastructure — the "we told you so" framing is in place for whenever an incident occurs. But Cat 1 reclassification could paradoxically reduce the probability by channeling demand from gray-market vendors (12–58% contamination) to regulated 503A/B compounders (USP 797/795 standards). Dual-direction signals cancel. No new actual safety incidents reported.
Reclassification to Cat 1 improves safety by bringing production under regulated compounding frameworks; gray-market sellers lose customers to legitimate pharmacies.
Held steady. Program extended through Dec 2027 — possibly an implicit acknowledgment that 6 months isn't enough for meaningful enrollment. Central processor mechanism (separate from Part D plans) confirmed as a friction point: no sponsor marketing engine, physician re-prescribing required, copay doesn't count toward deductible or OOP cap. BALANCE Model Medicaid launch in May is the key leading indicator.
Pent-up demand among 14M eligible beneficiaries overwhelms structural friction; $50/month for a $1,000+ drug is too compelling to resist.
The Augur's picks
PCAC appointment watch. Six vacancies, including the chair, on the Pharmacy Compounding Advisory Committee. Kennedy's appointments will determine the outcome of the July 23–24 meeting more than any safety dossier. Federal Register PCAC membership notices in May–June are the single highest-leverage leading indicator for both peptide forecasts. If pro-access members are appointed, the not-Cat-1 prediction breaks and the multi-peptide basket thesis strengthens further.
BALANCE Model as Medicare Bridge leading indicator. Medicaid GLP-1 enrollment under BALANCE starts May 2026. This is the first real-world datapoint for government GLP-1 program uptake patterns. Strong Medicaid uptake would weaken the <1M Medicare Bridge prediction; weak uptake would strengthen it. Two to three weeks until meaningful Medicaid data emerges.
---
How Barque got smarter today
- PCAC committee composition is the structural variable, not the evidence. The morning run focused on evidence (safety dossiers, political statements, stock moves). The afternoon signal harvest surfaced the mechanism: PCAC has 6 vacancies including the chair, and Kennedy controls appointments. This is a structural factor that supersedes the scientific debate. When you control who sits on the panel, the panel's recommendation is downstream of appointments, not evidence. Heuristic: in any advisory-committee forecast, check vacancy count and appointment authority before analyzing the evidence the committee will review.
- Investigative media is pre-positioning, not reacting. ProPublica published its Woodcock counter-narrative on April 3 — two weeks before the 12-peptide removal. Public Citizen followed. This isn't coverage of an event; it's preparation of a frame. The safety-incident prediction doesn't need an incident to have media infrastructure — the infrastructure is being built now, and will activate on whatever incident materializes. The Augur correctly identified this as a leading indicator.
- Dual-direction signals require holding, not forcing. The peptide-safety-incident forecast surfaced the cleanest example: Cat 1 reclassification simultaneously builds the media backlash narrative AND reduces gray-market contamination risk. The Bayesian correctly held at 0.65 rather than forcing a move in either direction. Holding is a decision, not an absence of decision.
- Confirming evidence earns small moves, not big ones. The Hims forecast moved +0.01 despite 10+ confirming sources (BofA, TIKR, multiple stock articles, Novo settlement). This is calibration discipline in action — confirmation is not surprise, and the Bayesian should not treat "more people agree" as "more likely to happen."
- The BALANCE Model is the next genuine signal. Medicaid GLP-1 enrollment under BALANCE starts May 2026. This is the first real-world data point for the Medicare Bridge uptake forecast. If Medicaid uptake is strong, the <1M Bridge prediction weakens. If weak, it strengthens. Flagging for active monitoring in 2–3 weeks.